Resected oropharyngeal cancer: “no benefit” from intensified adjuvant therapy
Access to the full content of this site is available only to registered healthcare professionals.
Register to read more
Adjuvant chemoradiotherapy (CRT) and boost doses of postoperative radiotherapy (B-PORT) are not associated with improved overall survival of patients with oropharyngeal squamous cell carcinoma (OPSCC) treated with primary surgery.
CRT (HR, 1.27; 95% CI, 0.70-2.30) and B-PORT (HR, 1.04; 95% CI, 0.63-1.73) were not significantly associated with improved overall survival.
Human papillomavirus (HPV) positivity (HR, 0.41; 95% CI, 0.21-0.80), positive surgical margins (HR, 2.15; 95% CI, 1.27-3.66), and ≥6 involved nodes (HR, 2.11; 95% CI, 1.13-3.93) were significantly associated with overall survival.
1409 patients with stage III to IVA-B OPSCC treated with primary surger...